What Incept LLC does

Incept LLC is a medical technology accelerator founded in 1998 by Amar Sawhney and Fred Khosravi, operating from Sunnyvale, California with operational activity in Bedford, Massachusetts. The firm identifies unmet clinical needs and builds, funds, and spins out independent portfolio companies rather than selling products directly, having launched 27 companies and achieved 16 exits to acquirers including Boston Scientific, Covidien, Teleflex, and Cardinal Health. Its central technical asset is the proprietary ELUTYX bioresorbable hydrogel platform, which has been licensed or deployed across portfolio companies including Ocular Therapeutix (DEXTENZA, AXPAXLI), Instylla (Embrace HES liquid embolics), Sealonix (PramStat hemostatic patch), and Rejoni (Juveena Hydrogel System).

The portfolio spans interventional stroke (Imperative Care's Zoom Stroke Solution, Kandu Health's digital recovery platform), interventional radiology (Instylla), ophthalmology (Ocular Therapeutix), surgical sealants (Sealonix), women's health (Rejoni), neurology diagnostics (StataDX), neuro-rehabilitation via brain-computer interface (Neurolutions), neural reflex therapies (Tulavi Therapeutics), mitral valve disease (Reniva), and life sciences analytics software (Axtria). Incept's competitive advantages rest on the founders' combined track record of 350+ patents, their National Academy of Engineering memberships, and the reusable hydrogel platform that compresses development timelines across specialties.

The business model is venture-creation rather than product commercialization: Incept earns value through equity stakes and eventual exits, with $6 billion in aggregate shareholder returns generated across 26 years and 1.3 million patients treated annually through portfolio company technologies. Portfolio companies raise their own development capital (over $1.4 billion cumulatively) and pursue their own FDA pathways, including recent 510(k) clearances for Imperative Care's Zoom RDL Radial Access System (January 2023) and Zoom 6F Insert Catheters (July 2024). Customer segments are therefore the portfolio companies and their eventual strategic acquirers in the medical device and pharmaceutical industries, not end-user healthcare providers.

Name

Incept LLC

Legal name

Incept LLC

Website

https://inceptllc.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Incept LLC is a medical technology accelerator founded in 1998 that builds and spins out life-sciences companies around its proprietary bioresorbable hydrogel platform, having launched 27 portfolio companies across stroke care, ophthalmology, interventional radiology, and neurology with 16 successful exits.

Ownership category

akta.pro rank

Product category

Medical Technology Accelerator

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Medical technology accelerator
• Medtech venture incubation
• Medical device innovation
• Life sciences ventures
• Healthcare portfolio development

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Accelerator/Investment Returns: Incept generates value through creating, nurturing, and spinning out medical technology companies. Success is measured through successful exits of portfolio companies and aggregate returns to shareholders, with over $6 billion in aggregate returns generated to date.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Incept LLC operates as a medical technology accelerator that identifies unmet clinical needs, nurtures medical device and biopharmaceutical innovations from concept through FDA clearance and commercialization, and spins out independent portfolio companies. The accelerator has launched 27 companies built around a proprietary bioresorbable hydrogel technology platform, with portfolio products spanning stroke treatment, interventional radiology, ophthalmology, surgical sealants, gynecology, neurology diagnostics, digital health, and cardiac therapy.

Product overview

Incept LLC is a medical technology accelerator that nurtures innovations from concept to commercialization through a portfolio of portfolio companies. The portfolio includes Imperative Care (Zoom Stroke Solution for stroke treatment), Instylla (Embrace liquid embolics for interventional radiology), Axtria (cloud-based life sciences software platforms), Ocular Therapeutix (DEXTENZA and AXPAXLI for eye diseases), Sealonix (hemostatic sealants), Rejoni (gynecological hydrogels), Kandu Health (stroke recovery digital health), Neurolutions (brain-computer interface rehabilitation), StataDX (neurology diagnostics), Tulavi Therapeutics (neural therapies), and Reniva (cardiac therapies). Each company operates independently with its own products and technologies spanning medical devices, digital health, and biopharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• Imperative Care (Zoom Stroke Solution) Comprehensive stroke system from access through reperfusion for acute ischemic stroke, including Zoom 6F Insert Catheters, Zoom 88 Large Distal Platform, Zoom RDL Radial Access Platform, vessel-matched Zoom Aspiration Catheters, Zoom Pump, and Zoom POD, sold to hospitals and stroke centers.
• Instylla (Embrace Hydrogel Embolic System)

Quantifiable outcome

• 1.3 million patients treated annually with devices developed by Incept companies
• +2 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

14 partnerships are on record, tiered core.

• NovartiscoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event and representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• MerckcoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event with executive Abhishek Narayan Singh receiving Ignite Leadership Award.
• PfizercoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• TakedacoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event with executive Steve Winawer receiving Ignite Leadership Award.
• GSKcoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event with executive Cary Anne Schockemoehl receiving Ignite Leadership Award.
• AstraZenecacoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• SanoficoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• Johnson & JohnsoncoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• Gilead SciencescoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event with executive Chitra Narasimhachari receiving Ignite Leadership Award.
• AmgencoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• Bristol-Myers Squibb (BMS)coreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• BayercoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.
• RegeneroncoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally. Executive Arvind Balasundaram received Ignite Leadership Award.
• BiogencoreStrategic or Co-development PartnerMajor pharmaceutical company participating in Axtria Ignite 2024 event representing one of Axtria's client base of 16 of the top 20 life sciences companies globally.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• NXT Biomedical: Medtech incubator founded by former Incept/Foundry principals that incubates early-stage cardiovascular and structural heart companies, sharing Incept's company-creation DNA.
• Fogarty Institute for Innovation: Non-profit medtech incubator that nurtures physician-innovated device startups from concept through clinical milestones. Operates a comparable accelerator model focused on cardiovascular and structural heart innovation.
• ExploraMed: Medical device incubator founded by Josh Makower that creates and spins out minimally invasive device companies. Closely mirrors Incept's physician-driven, idea-to-commercialization medtech creation model.
• The Foundry: Pioneering medical device incubator/company-creation studio founded by Hanson Gifford that, like Incept, identifies unmet clinical needs, builds companies around novel technologies, and exits via strategic acquisition.

Emerging players

• MedTech Innovator: Non-profit medtech accelerator and venture competition that accelerates startups from concept through commercialization, overlapping with Incept's pipeline-supporting role.
• Petri: Early-stage biotech accelerator backing scientists building breakthrough companies. Comparable as a life-sciences accelerator/company-creation studio, though focused on therapeutics rather than devices.
• IndieBio: Biology-focused startup accelerator that funds and incubates early-stage biotech companies; overlaps with Incept's life-sciences creation mandate but tilts more toward synthetic biology and therapeutic platforms than devices.

Broad incumbents

• Leaps by Bayer: Bayer's corporate venture and breakthrough innovation arm investing in and building companies across healthcare and agriculture. Functions as a corporate-backed accelerator at a vastly greater scale than Incept.
• JLABS (Johnson & Johnson Innovation): Johnson & Johnson's no-strings-attached life sciences incubator network. Operates a much larger portfolio across pharma, medtech, and consumer health but follows a similar 'nurture early-stage innovation' accelerator philosophy.

Others

• Stanford Byers Center for Biodesign: Academic medtech innovation program that trains innovators and spins out device companies addressing unmet clinical needs; functions as an ideas-and-talent feeder to accelerators like Incept.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Incept LLC